• Strategic Survivin Inhibition: YM-155 Hydrochloride in Trans

  2026-06-09

  Explore how YM-155 hydrochloride, a selective survivin inhibitor from APExBIO, is redefining translational cancer research. This article combines mechanistic insights, evidence-based protocol strategies, and a cross-analysis of emerging in vitro methodologies to guide researchers in leveraging YM-155 hydrochloride for advanced apoptosis inhibitor research and tumor regression studies.

• Amyloid Beta-peptide (25-35): Deep Mechanistic Insights for

  2026-06-09

  Explore the advanced mechanistic roles of Amyloid Beta-peptide (25-35) in neurodegenerative disease research. This article delivers unique insight into microglial polarization, experimental design, and translational assay decisions using Aβ25-35 for Alzheimer's disease models.

• FPH1 (BRD-6125) Transforms Hepatocyte Proliferation Workflow

  2026-06-08

  FPH1 (BRD-6125) enables robust, donor-independent expansion of functional human hepatocytes for drug discovery and regenerative medicine. Its optimized use in primary culture and iPS-derived hepatocyte differentiation unlocks scalable, reproducible platforms now essential for advanced cell-based and gene therapy research.

• Cyclosporin A: Technical Guide for Immunosuppression Researc

  2026-06-08

  Cyclosporin A (SKU B1922) is a potent cyclophilin inhibitor used to dissect immune suppression, mitochondrial regulation, and apoptosis in cell and animal models. It is best suited for studies on autoimmune mechanisms, viral entry inhibition, and retinal ischemic injury, but should not be used where water solubility is required or long-term solution stability is critical.

• EZ Cap EGFP mRNA 5-moUTP: Enhanced Reporter mRNA Workflows

  2026-06-07

  EZ Cap™ EGFP mRNA (5-moUTP) from APExBIO empowers researchers with next-generation mRNA stability, immune evasion, and robust fluorescent protein expression. This guide translates bench research into actionable protocols, highlights optimization strategies, and connects core innovations to advanced delivery and imaging applications.

• H-89: Advanced cAMP-Dependent Protein Kinase Inhibitor Use

  2026-06-06

  Leverage H-89 for precise cAMP signaling pathway modulation, enabling robust dissection of metabolic rewiring in osteogenesis and apoptosis research. This guide translates the latest mechanistic insights into actionable workflows, troubleshooting, and optimization for cell signaling assays.

• Lovastatin: Mechanisms, Workflows, and Translational Impact

  2026-06-05

  Explore how Lovastatin, a potent HMG-CoA reductase inhibitor, bridges mechanistic insight with translational strategy. This article delivers actionable guidance for leveraging Lovastatin in cancer, apoptosis, and metabolic research, referencing APExBIO’s product and recent advances. Grounded in primary literature and real-world protocols, it sets a new benchmark for scientific leadership in biomedical workflows.

• FGF4-FGFR1 Signaling Preserves Podocytes in Diabetic Kidney

  2026-06-05

  This study identifies podocyte-secreted FGF4 as a central regulator of glomerular health in diabetic kidney disease (DKD), demonstrating that FGF4 activates FGFR1-AMPK-FOXO1 signaling to prevent podocyte loss and renal dysfunction. The findings highlight FGFR signaling as a promising therapeutic target for DKD.

• Human iPSC-Derived Sensory Neuron Model for HSV-1 Latency

  2026-06-04

  This study establishes a robust protocol for differentiating human inducible pluripotent stem cells into functional sensory neurons and validates their use as a scalable in vitro model for herpes simplex virus 1 (HSV-1) latency and reactivation. These findings address a key gap in translational virology by providing a human neuronal system to dissect the mechanisms underlying HSV-1 latent infection and reactivation, potentially accelerating antiviral research and therapeutic development.

• Lovastatin in Applied Research: Protocols, Workflows, and Op

  2026-06-04

  Lovastatin stands out as a potent HMG-CoA reductase inhibitor with unique applications across cancer, apoptosis, and cell proliferation studies. This guide details evidence-based workflows, troubleshooting strategies, and novel protocol adaptations for maximizing success in high-impact biomedical research.

• EZ Cap™ Mouse IL-12 mRNA (m1Ψ): Mechanisms and Next-Gen Immu

  2026-06-03

  Explore the science and application of EZ Cap™ Mouse IL-12 mRNA (m1Ψ) in immunotherapy research. This article uniquely dissects its molecular advantages, delivery innovations, and the translational impact of recent virus-mimicking delivery systems.

• Leupeptin Hemisulfate Salt: Precision in Protease Activity R

  2026-06-03

  Leupeptin hemisulfate salt is a nanomolar, reversible inhibitor of serine and cysteine proteases. It is widely used for protein degradation studies, viral replication inhibition, and autophagy research. APExBIO’s product offers validated, reproducible performance across biochemical workflows.

• Structure-Based Discovery of SARS-CoV-2 NSP15 Inhibitors

  2026-06-02

  This article reviews a structure-based virtual screening study that identified thymopentin and oleuropein as potent inhibitors of SARS-CoV-2 NSP15, an endoribonuclease involved in viral evasion of host immunity. The findings illustrate the power of computational approaches in expanding the antiviral drug discovery toolkit and highlight new avenues for therapeutic intervention against COVID-19.

• CGF Induces ROS-Mediated Cell Cycle Arrest in Colorectal Can

  2026-06-02

  This study characterizes the anthocyanin derivative CGF, extracted from purple sweet potato, as a potent suppressor of colorectal cancer (CRC) progression. CGF mediates its antitumor effects through ROS-driven metabolic reprogramming, mitochondrial dysfunction, and targeted disruption of cell cycle and apoptosis signaling, highlighting a promising molecular mechanism and preclinical therapeutic strategy.

• Acetoacetic Acid Sodium Salt in Advanced Energy Metabolism R

  2026-06-01

  Acetoacetic acid sodium salt (sodium 3-oxobutanoate) from APExBIO is redefining experimental workflows for diabetes and energy metabolism studies. This article delivers actionable protocols, troubleshooting insights, and cross-domain innovation, enabling researchers to achieve more reproducible and interpretable outcomes.

11175 records 1/745 page Next 12345 下5页 Last page